Paris, March 6th 2013 - Bryan, Garnier & Co, the independent pan-European Investment bank focusing on growth companies, acts as joint bookrunner for a €45 million private placement for Ablynx, including €31.5 million of new shares.
This new placement will allow Ablynx to:
• Maintain the momentum of ALX-0061 and review paths which could allow the value of this asset to be maximized
• Flexibly manage the structure of timing of potential deals
• Initiate, advance and/or accelerate the pre-clinical development for various programs
Ablynx is a biopharmaceutical company headquartered in Ghent, Belgium. With its proprietary technology platform, Nanobody, a novel class of therapeutic proteins based on single-domain antibody fragments, Ablynx has built multiple programs targeting various diseases, including inflammation, oncology, and Alzheimer’s disease, and also collaborated with leading pharmaceutical companies in the industry.
In spite of challenging equity markets, the success of this placement clearly indicates strong investor appetite for promising European healthcare mid-cap companies investing in future developments. Furthermore, the market remains an efficient purveyor of liquidity for the historical shareholders of mid-cap companies such as venture capital and private equity funds.
Bryan, Garnier & Co acted as Joint Bookrunner for the placement.
For more information please contact Anna Emelianenko /+33 (0) 1 56 68 75 67 / email@example.com
Headquartered in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, haematology, oncology and pulmonary disease. To date, Ablynx has generated Nanobodies against more than 235 different disease targets and has approximately 25 programs in the pipeline and 5 nanobodies at clinical development stage. Due to its proprietary technology platform, Nanobody, and its experienced management team, Ablynx has already successfully built collaborations with many leading pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The successful Phase II results of Ablynx’s flagship product, ALX-0061, which targets at the treatment of rheumatoid arthritis have been published in Feb 2013.
About Bryan, Garnier & Co
Bryan, Garnier & Co is an independent investment bank specialized in European TMT, Healthcare and Renewable Energies growth companies. Bryan, Garnier & Co is positioned in three activities: Equity Research & Brokerage, Asset Management and Corporate Finance.
With more than 150 professionals based in London, Paris, New Delhi, New York and Geneva, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique.
Through its corporate finance practice, Bryan, Garnier & Co has became a leader in advising European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital market, LBOs and private placement over the last three years.
Bryan, Garnier & Co is authorized and regulated by the Financial Services Authority (FSA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext ListingSponsor, and is active on all European capital markets.